Article

Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide

Department of Clinical Biochemistry, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Osteoporosis International (Impact Factor: 4.17). 10/2010; 22(6):1935-46. DOI: 10.1007/s00198-010-1379-y
Source: PubMed

ABSTRACT We report the changes in biochemical markers of bone formation during the first 6 months of teriparatide therapy in postmenopausal women with osteoporosis according to previous antiresorptive treatment. Prior therapy does not adversely affect the response to teriparatide treatment. Similar bone markers levels are reached after 6 months of treatment.
The response of biochemical markers of bone turnover with teriparatide therapy in subjects who have previously received osteoporosis drugs is not fully elucidated. We examined biochemical markers of bone formation in women with osteoporosis treated with teriparatide and determined: (1) whether the response is associated with prior osteoporosis therapy, (2) which marker shows the best performance for detecting a response to therapy, and (3) the correlations between early changes in bone markers and subsequent bone mineral density (BMD) changes after 24 months of teriparatide.
We conducted a prospective, open-label, 24-month study at 95 centers in 10 countries in 758 postmenopausal women with established osteoporosis (n = 181 treatment-naïve) who had at least one post-baseline bone marker determination. Teriparatide (20 μg/day) was administered for up to 24 months. We measured procollagen type I N-terminal propeptide (PINP), bone-specific alkaline phosphatase (b-ALP), and total alkaline phosphatase (t-ALP) at baseline, 1 and 6 months, and change in BMD at the lumbar spine, total hip and femoral neck from baseline to 24 months.
Significant increases in formation markers occurred after 1 month of teriparatide regardless of prior osteoporosis therapy. The absolute increase at 1 month was lower in previously treated versus treatment-naïve patients, but after 6 months all groups reached similar levels. PINP showed the best signal-to-noise ratio. Baseline PINP correlated positively and significantly with BMD response at 24 months.
This study suggests that the long-term responsiveness of bone formation markers to teriparatide is not affected in subjects previously treated with antiresorptive drugs.

Download full-text

Full-text

Available from: Fernando Marin, Aug 10, 2015
1 Follower
 · 
116 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Thesis (Ph. D.)--Stanford University, 1997. Submitted to the School of Education. Copyright by the author.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Through the dynamification of testing intervals the flexibility level of confirmation systems for measuring equipment can be increased considerably. Since confirmation of inspection, measuring and testing equipment is a significant part of quality management and an essential requirement for the entire production process, especially with the increasing demands of micro- and nanotechnology, it is absolutely necessary to increase the efficiency of confirmation systems. Through a special method developed for this purpose, the flexibility level and efficiency of confirmation systems can be achieved and the expenses can be substantially reduced by the use of fuzzy logic for dynamification of testing intervals
    Intelligent Processing and Manufacturing of Materials, 1999. IPMM '99. Proceedings of the Second International Conference on; 02/1999
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We recently reported that subantimicrobial-dose doxycycline (SDD) significantly reduced serum bone-resorption biomarkers in subgroups of post-menopausal women. We hypothesize that changes in serum bone biomarkers are associated not only with systemic bone mineral density (BMD) changes, but also with alveolar bone changes over time. One hundred twenty-eight eligible post-menopausal women with periodontitis and systemic osteopenia were randomly assigned to receive SDD or placebo tablets twice daily for two years, adjunctive to periodontal maintenance. Sera were analyzed for bone biomarkers. As expected, two-year changes in a serum bone biomarker were significantly associated with systemic BMD loss at the lumbar spine (osteocalcin, bone-turnover biomarker, p = 0.0002) and femoral neck (osteocalcin p = 0.0025). Two-year changes in serum osteocalcin and serum pyridinoline-crosslink fragment of type I collagen (ICTP; bone-resorption biomarker) were also significantly associated with alveolar bone density loss (p < 0.0001) and alveolar bone height loss (p = 0.0008), respectively. Thus, we have shown that serum bone biomarkers are associated with not only systemic BMD loss, but with alveolar bone loss as well. Clinical Trial Registration Information: Protocol registered at ClinicalTrials.gov, NCT00066027.
    Journal of dental research 03/2011; 90(6):747-51. DOI:10.1177/0022034511402993 · 4.14 Impact Factor
Show more